Bacterial Superinfections After SARS-CoV-2 Pneumonia: Antimicrobial Resistance Patterns, Impact on Inflammatory Profiles, Severity Scores, and Clinical Outcomes
- PMID: 40422577
- PMCID: PMC12109590
- DOI: 10.3390/diseases13050145
Bacterial Superinfections After SARS-CoV-2 Pneumonia: Antimicrobial Resistance Patterns, Impact on Inflammatory Profiles, Severity Scores, and Clinical Outcomes
Abstract
Background and Objectives: Secondary bacterial pneumonia can substantially worsen the clinical trajectory of patients hospitalized for Coronavirus Disease 2019 (COVID-19). This study aimed to characterize bacterial superinfections in COVID-19, including pathogen profiles, resistance patterns, inflammatory responses, severity scores, and ICU admission risk. Methods: In a retrospective cohort design, we reviewed 141 patients admitted to a single tertiary-care hospital between February 2021 and December 2024. A total of 58 patients had laboratory-confirmed bacterial superinfection by sputum, bronchoalveolar lavage, or blood cultures (superinfection group), whereas 83 had COVID-19 without any documented bacterial pathogens (COVID-only group). We collected detailed microbiological data from sputum, bronchoalveolar lavage (BAL), and blood cultures. Antibiotic sensitivity testing was performed using standard breakpoints for multidrug resistance (MDR). Inflammatory markers (C-reactive protein, procalcitonin, neutrophil-to-lymphocyte ratio, and systemic immune-inflammation index) and the severity indices Acute Physiology and Chronic Health Evaluation (APACHE) II, Confusion, Urea, Respiratory rate, Blood pressure (CURB), and National Early Warning Score (NEWS) were measured at admission. Primary outcomes included intensive care unit (ICU) admission, mechanical ventilation, and mortality. Results: Patients in the superinfection group showed significantly elevated inflammatory markers and severity scores compared to the COVID-only group (mean APACHE II of 17.2 vs. 13.8; p < 0.001). Pathogens most frequently isolated from sputum and BAL included Klebsiella pneumoniae (27.6%) and Pseudomonas aeruginosa (20.7%). Multidrug-resistant strains were documented in 32.8% of isolates. The superinfection group had higher ICU admissions (37.9% vs. 19.3%; p = 0.01) and more frequent mechanical ventilation (25.9% vs. 9.6%; p = 0.01). Mortality trended higher among superinfected patients (15.5% vs. 7.2%; p = 0.09). A total of 34% of the cohort had prior antibiotic use, which independently predicted MDR (aOR 2.6, p = 0.01). The presence of MDR pathogens such as Klebsiella pneumoniae (OR 2.8), Pseudomonas aeruginosa (OR 2.5), and Staphylococcus aureus (OR 2.1) significantly increases the risk of ICU admission. Conclusions: Bacterial superinfection exacerbates inflammation and worsens outcomes in COVID-19 patients, such as a higher risk of ICU admission.
Keywords: COVID-19; antimicrobial resistance; bacterial infections; intensive care unit; pneumonia.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Fungal Pulmonary Coinfections in COVID-19: Microbiological Assessment, Inflammatory Profiles, and Clinical Outcomes.Biomedicines. 2025 Apr 3;13(4):864. doi: 10.3390/biomedicines13040864. Biomedicines. 2025. PMID: 40299432 Free PMC article.
-
Incidence and clinical outcomes of bacterial superinfections in critically ill patients with COVID-19.Front Med (Lausanne). 2023 Mar 2;10:1079721. doi: 10.3389/fmed.2023.1079721. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36936237 Free PMC article.
-
Inflammatory Markers and Severity in COVID-19 Patients with Clostridioides Difficile Co-Infection: A Retrospective Analysis Including Subgroups with Diabetes, Cancer, and Elderly.Biomedicines. 2025 Jan 17;13(1):227. doi: 10.3390/biomedicines13010227. Biomedicines. 2025. PMID: 39857810 Free PMC article.
-
Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia.Semin Respir Crit Care Med. 2009 Feb;30(1):116-23. doi: 10.1055/s-0028-1119815. Epub 2009 Feb 6. Semin Respir Crit Care Med. 2009. PMID: 19199193 Review.
-
Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis.PLoS One. 2021 May 6;16(5):e0251170. doi: 10.1371/journal.pone.0251170. eCollection 2021. PLoS One. 2021. PMID: 33956882 Free PMC article.
References
-
- Pfortmueller C.A., Spinetti T., Urman R.D., Luedi M.M., Schefold J.C. COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment—A narrative review. Best Pract. Res. Clin. Anaesthesiol. 2021;35:351–368. doi: 10.1016/j.bpa.2020.12.011. - DOI - PMC - PubMed
-
- Adelman M.W., Bhamidipati D.R., Hernandez-Romieu A.C., Babiker A., Woodworth M.H., Robichaux C., Murphy D.J., Auld S.C., Kraft C.S., Jacob J.T. Emory COVID-19 Quality and Clinical Research Collaborative members. Secondary Bacterial Pneumonias and Bloodstream Infections in Patients Hospitalized with COVID-19. Ann. Am. Thorac. Soc. 2021;18:1584–1587. doi: 10.1513/AnnalsATS.202009-1093RL. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous